Vijoice

Active Ingredient(s): Alpelisib
FDA Approved: * April 5, 2022
Pharm Company: * NOVARTIS PHARMS CORP
Category: Cancer

Alpelisib, sold under the brand name Piqray (as Pivikto in emerging markets), is a medication sold by Novartis and used to treat certain types of breast cancer.[5] It is used together with fulvestrant.[5] It is taken by mouth.[5]it is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced ... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Vijoice 50 mg Oral Tablet
NDC: 0078-1021
Labeler:
Novartis Pharmaceuticals Corporation
Vijoice 125 mg Oral Tablet
NDC: 0078-1028
Labeler:
Novartis Pharmaceuticals Corporation
VijoiceVijoice Kit
NDC: 0078-1035
Labeler:
Novartis Pharmaceuticals Corporation
Vijoice 50 mg Oral Granule
NDC: 0078-1175
Labeler:
Novartis Pharmaceuticals Corporation

Related Brands

Drugs with the same active ingredients